<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9A22541F-DA58-481E-8D0C-C4BCF4EA030E"><gtr:id>9A22541F-DA58-481E-8D0C-C4BCF4EA030E</gtr:id><gtr:name>EMBL - European Bioinformatics Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB10 1SD</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Centre for Cutaneous Research / ICMS</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9A22541F-DA58-481E-8D0C-C4BCF4EA030E"><gtr:id>9A22541F-DA58-481E-8D0C-C4BCF4EA030E</gtr:id><gtr:name>EMBL - European Bioinformatics Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB10 1SD</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CA2294D2-CD9B-4225-B801-BC35FDE1A758"><gtr:id>CA2294D2-CD9B-4225-B801-BC35FDE1A758</gtr:id><gtr:firstName>Priya</gtr:firstName><gtr:surname>Dewan</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901967"><gtr:id>55AED81B-C91F-4B64-96E4-EF0A8B1E630D</gtr:id><gtr:title>Identification of novel targetable signalling pathways in the inherited ichthyoses</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0901967</gtr:grantReference><gtr:abstractText>The ichthyoses are a group of rare inherited skin diseases characterised by dry, scaly skin. Ichthyoses have a major impact on quality of life and severe cases can be life-threatening with a major effect on quality of life for both affected child and family. Topical treatments provide limited symptomatic relief only, and available systemic treatments (acitretin and isotretinoin) are not very effective and have major side effects, including an effect on the unborn child. There remains an unmet clinical need for safe and efficacious treatments targeting the different ichthyoses. As the clinical appearance of many of the ichthyoses are similar despite diverse genetic defects, we believe that it may be possible to identify common pathways using engineered skin models with deficiencies in the relevant genes from the same genetic background. High-throughput computer analysis will be used to identify these pathways, which will then be confirmed in patient samples with known defects in the same genes. The identification of new targets in the ichthyoses could encourage drug development in this area and may even allow identification of known drugs that could be used as an alternative to current treatment.</gtr:abstractText><gtr:technicalSummary>Background:
The ichthyoses are a diverse group of inherited diseases, ranging from mild (ichthyosis vulgaris) to very severe (harlequin ichthyosis). As all of the genetic defects elucidated affect terminal differentiation in skin and all cause a similar clinical phenotype of varying severity, we hypothesise that it may be possible to identify common signalling pathways invoved in disease pathogenesis.
Aims and Objectives:
1. Development and simple characterisation of in vitro models for the ichthyoses, to include the most common and the most severe phenotypes.
2. Microarray gene expression analysis on engineered epidermis from the same genetic background with knockdown of relevant ichthyosis genes.
3. Validation of results using archival patient samples and in vitro experiments with known inhibitors.
Methodology:
Knockdown of ichthyosis genes in telomerase immortalised human keratinocytes (N-TERT) will be achieved using siRNAs targeting ABCA12 (harlequin ichthyosis), TGM1 (lamellar ichthyosis, congenital ichthyosiform erythroderma), ALOX12B (CIE, milder phenotype), STS (X-linked ichthyosis) and FLG (ichthyosis vulgaris). Knock-down will be confirmed and quantified by immunoblotting and q-PCR. Organotypic (three-dimensional) cultures will be generated using de-epidermalised dermis, normal fibroblasts and knock-down or control keratinocytes (scrambled non-targeting). Sections from the organotypic cultures will be immunostained for early (K14, K1) and late (K2e, involucrin) differentiation markers. RNA extraction and quantification will be performed from generated disease models and control epidermis. The Illumina gene expression analysis platform (Human HT12 Beadchip assaying 48,000 transcripts from 12 samples) will be used to compare quadruplicate biological replicates. Data will be generated using the equipment within Barts and the London SMD?s Genome Centre. Signalling pathway analysis will be performed using Ingenuity Pathfinder in collaboration with Richard Dobson, Bioinformatician. Quantitative PCR using the Opticon 2 system will be used to confirm altered gene expression. Signalling networks in common will then be validated using sections from patients with known mutations.
Scientific opportunities:
This project will provide me with cell and molecular biology skills including monolayer and complex cell culture, siRNA, gene expression array analysis, western blotting, Q-PCR, confocal microscopy and immunohistochemistry.
Medical opportunities:
Identification of new targetable pathways in the ichthyoses is an exciting prospect.</gtr:technicalSummary><gtr:fund><gtr:end>2013-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>221127</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>EMBL European Bioinformatics Institute (EMBL - EBI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EBI</gtr:description><gtr:id>8C31A7A0-62FC-45AD-B13F-08B3DC5B13A7</gtr:id><gtr:impact>Enright group-Bioinformatics</gtr:impact><gtr:outcomeId>546daf3cdb8b55.27210222-1</gtr:outcomeId><gtr:partnerContribution>RNASeq analysis for this project was done in collaboration with the Enright Group, EBI (http://www.ebi.ac.uk/research/enright).</gtr:partnerContribution><gtr:piContribution>Gene silencing (6 ichthyoses genes), RNA extraction, further validation of results obtained after RNASeq data analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GSK</gtr:description><gtr:id>2DCE17F3-1C1A-44CF-A6FB-EE0734E25C0C</gtr:id><gtr:impact>RNA seq data analysis in collaboration with EBI</gtr:impact><gtr:outcomeId>546db2bac45c98.75746469-1</gtr:outcomeId><gtr:partnerContribution>RNA sequencing-Illumina platform</gtr:partnerContribution><gtr:piContribution>Gene silencing, RNA extraction, further validation of results obtained after RNASeq data analysis</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>British Society of Investigative Dermatology</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B5C67DEF-B330-4C1F-8870-1E92D43790FF</gtr:id><gtr:impact>Questions and discussions

Discussion</gtr:impact><gtr:outcomeId>546db124de31d8.75350818</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Barrier Function of Mammalian Skin Gordon Research Conference</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DAE5B910-1588-499A-9965-1020754584BF</gtr:id><gtr:impact>This is a multidisciplinary conference attended by academics, industry and clinicians. This environment facilitated discussions and interactions with the possibility of future collaborations. 

Barrier Function of Mammalian Skin,
August 18-23, 2013
Waterville Valley Resort
Waterville Valley, NH
USA

Possiblr collaboration for chromatography</gtr:impact><gtr:outcomeId>BQAujd3yp4z</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.grc.org/programs.aspx?year=2013&amp;program=barrier</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G0901967</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7EE9741E-CF94-420A-B0AB-A7811523CF2C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Skin</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>